Vulvar Carcinoma (Vulvar Cancer): Disease Characteristics Research Report

Target Disease

• Disease name: Vulvar carcinoma (vulvar cancer)
• Category: Malignant neoplasm of the vulva (female genital tract cancer)
• MONDO ID: Not available from the retrieved sources in this run (would require dedicated ontology lookup).

1. Disease Information

Overview (what is the disease?)

Vulvar carcinoma is an uncommon malignant tumor arising in vulvar tissues; vulvar squamous cell carcinoma (VSCC) is the predominant histologic subtype (≈90% of vulvar cancers in multiple reviews). (corte2024currentpreoperativemanagement pages 1-2)

Key identifiers and terminologies

• ICD-10: C51 (vulval/vulvar cancer) is explicitly used in health system cost and epidemiology analyses. (steinkasserer2023characterizationofpatients pages 1-2)
• ICD-O-3 site coding: HPV-related cancer epidemiology work referenced ICD-O-3 site codes including C51.0 for vulvar cancer. (adekanmbi2024humanpapillomavirusvaccination pages 1-2)
• MeSH (term): A 2024 imaging review searched PubMed using MeSH terms including “vulval neoplasm” (and “diagnostic imaging”). (ha2024imaginginvulval pages 1-2)
• FIGO staging: The FIGO 2021 revision is data-derived and explicitly allows incorporation of cross-sectional imaging findings into staging. (olawaiye2021figostagingfor pages 1-2)

Common synonyms / alternative names

• Vulvar carcinoma; vulval cancer; vulvar cancer; vulvar squamous cell carcinoma (VSCC) (dominant histology). (corte2024currentpreoperativemanagement pages 1-2)

Evidence-source note (individual patient vs aggregated)

This report is derived from aggregated disease-level resources (reviews, guidelines syntheses, cohort/registry studies, and clinical trial registry entries) plus some single-center retrospective cohorts and experimental model studies. (corte2024currentpreoperativemanagement pages 1-2, dongre2024tp53mutationand pages 1-2, meng2024overallsurvivalassociated pages 1-2, dongre2020establishmentofa pages 1-7)

2. Etiology

Core causal pathways (current understanding)

Modern classification recognizes two main etiologic pathways for VSCC: 1. HPV-associated VSCC: often basaloid/warty morphology; typically p16 “block” positive; generally occurs in younger patients and is associated with precursor high-grade squamous intraepithelial lesions (HSIL/usual VIN). (dongre2024tp53mutationand pages 1-2, horn2024molecularsubtypesof pages 12-14, hohn20212020whoclassification pages 4-6) 2. HPV-independent VSCC: often keratinizing morphology; frequently linked to chronic inflammatory vulvar dermatoses (notably lichen sclerosus) and to differentiated VIN (dVIN); commonly shows aberrant p53 patterns consistent with TP53 alteration; generally associated with poorer prognosis. (dongre2024tp53mutationand pages 1-2, horn2024molecularsubtypesof pages 12-14, horn2024molecularsubtypesof pages 16-18)

A recent focus is the less common HPV-independent/p53-wild-type subtype, emphasizing that not all HPV-independent tumors are p53-abnormal. (horn2024molecularsubtypesof pages 12-14)

Risk factors

Infectious: high-risk HPV infection is a major risk factor for HPV-associated disease; HPV16 is predominant among HPV-positive high-grade vulvar lesions in one 2024 review (HPV16 ≈80% of HPV-positive cases). (scurtu2024squamouscellcarcinoma pages 5-7)

Inflammatory/dermatologic: lichen sclerosus (LS) is strongly associated with HPV-independent precancers and cancer and can lead to SCC development; LS causes chronic inflammation and tissue remodeling that may support carcinogenesis. (luca2023lichensclerosusthe pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

Precursor lesions: differentiated VIN (dVIN) is a high-risk HPV-independent precursor; one 2024 review reports much higher progression for dVIN than HSIL (43.2% vs 9.7%). (scurtu2024squamouscellcarcinoma pages 4-5)

Host factors: immunosuppression is highlighted as a critical cofactor for HPV-associated lesions in a recent review. (scurtu2024squamouscellcarcinoma pages 5-7)

Protective factors

HPV vaccination: Multiple sources support prophylactic HPV vaccination as a key protective factor against HPV-associated disease, with very high efficacy in HPV-naïve individuals. - A large 2024 cross-sectional study notes vaccine efficacy “close to 100%” for preventing HPV-associated cancers among those without prior infection with vaccine HPV types. (adekanmbi2024humanpapillomavirusvaccination pages 1-2) - A 2024 review of HPV vaccine strategies states that vaccination blocks transmission and prevents HPV-related cancers and reports global implementation but limited coverage (143 member states by end of 2023; ~15% of young girls vaccinated). (cai2024humanpapillomavirusrelatedcancer pages 1-2)

Management of lichen sclerosus (risk reduction plausibility): LS reviews and cohorts emphasize the need for early diagnosis, adequate treatment, and follow-up to reduce malignant evolution risk. - A 2024 LS review reports markedly elevated vulvar cancer risk in LS (example population-based SIR 33.6 for vulvar cancer) and suggests that consistent long-term potent topical corticosteroid (TCS) use may reduce recurrence compared with historical recurrence rates. (popa2024vulvarlichensclerosus pages 21-22)

Gene–environment interactions

Direct quantitative gene–environment interaction estimates were not present in the retrieved evidence. Mechanistically, LS-associated chronic inflammation/oxidative stress provides an enabling microenvironment for carcinogenesis and can co-occur with TP53 pathway alterations typical of HPV-independent disease. (luca2023lichensclerosusthe pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

3. Phenotypes (clinical presentation, signs/symptoms, QoL)

Common presenting symptoms/signs (VSCC)

Recent clinical updates emphasize that presentation ranges from asymptomatic lesions detected on exam to symptomatic disease with: - vulvar pruritus (itching) - pain/burning - lump/mass - ulcer These features are highlighted in recent clinical overviews and updates. (corte2024currentpreoperativemanagement pages 1-2, olawaiye2021cancerofthe pages 1-2)

Age of onset / demographics

VSCC predominantly affects postmenopausal women with mean/median ages often >65–70 years in clinical series and reviews; HPV-associated cases skew younger. (corte2024currentpreoperativemanagement pages 1-2, cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4, dongre2024tp53mutationand pages 1-2)

Quality-of-life impacts

Major QoL burdens stem from symptoms (pain/pruritus), genital functional impairment, and treatment morbidity. - Conservative approaches (e.g., sentinel node biopsy) are emphasized to reduce long-term morbidity such as chronic lymphedema, wound issues, and sexual dysfunction. (cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4, kolk2024updateonthe pages 1-2)

Suggested HPO terms (examples)

(These are ontology suggestions; HPO IDs are provided where commonly used—verify in HPO browser for exact IDs.) - Pruritus (HP:0000989) - Vulvar pain (term exists in HPO; verify exact ID) - Genital ulcer (HP:0000211, general mucosal ulceration; vulvar-specific term should be checked) - Vulvar mass (term exists; verify exact ID) - Lymphedema (HP:0001004) (treatment complication) (cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4) - Dyspareunia (HP:0000148) (common in LS and survivorship context) (luca2023lichensclerosusthe pages 1-2)

4. Genetic / Molecular Information

Molecular classification and defining biomarkers

WHO-era classification of vulvar SCC emphasizes HPV association using p16 as a surrogate marker and p53 immunophenotyping for HPV-independent disease (with a recognized “uncertain” group). (hohn20212020whoclassification pages 4-6, horn2024molecularsubtypesof pages 16-18)

• HPV-associated: p16 block-positive; often p53 wild-type pattern; typically better prognosis/radiosensitivity. (hohn20212020whoclassification pages 4-6)
• HPV-independent: often p16 negative/non-block; frequently p53 aberrant (overexpression, null, cytoplasmic) consistent with TP53 alteration. (horn2024molecularsubtypesof pages 16-18)

Recurrent somatic alterations (VSCC)

2024 Japanese VSCC genomic profiling: TP53 (52–81%), HRAS (7–26%), CDKN2A (21–24%), PIK3CA (5–10%). (fujii2024genomicprofilesof pages 1-2)

HPV-status–linked molecular profiles (tumor sequencing cohort): HPV-independent tumors show high rates of TP53, TERT promoter, CDKN2A, NOTCH1, FAT1 alterations, while HPV-associated tumors are enriched for activating PIK3CA mutations (PI3K pathway). (salama2022molecularlandscapeof pages 1-3)

Mechanistic/pathway summary (causal chain)

• HPV-associated pathway: viral oncoproteins (E6/E7/E5) enable immune evasion and drive carcinogenesis; E6/E7 disrupt tumor suppressor pathways, with downstream cell-cycle dysregulation and p16 overexpression. (scurtu2024squamouscellcarcinoma pages 5-7)
• HPV-independent pathway: chronic inflammation (e.g., LS) and precursor dVIN are linked to TP53 mutagenic processes, NOTCH1 loss-of-function, and RTK/RAS/PI3K signaling (including HRAS involvement), driving clonal expansion and invasion. (scurtu2024squamouscellcarcinoma pages 5-7, fujii2024genomicprofilesof pages 1-2)

Suggested GO biological process terms (examples)

• Epithelial cell proliferation (GO:0050673)
• Keratinocyte differentiation (GO:0030216)
• Cell cycle regulation (GO:0051726)
• DNA damage response (GO:0006974)
• Regulation of apoptotic process (GO:0042981)
• Response to virus (GO:0009615) (HPV-associated)

Suggested CL (cell type) terms (examples)

• Keratinocyte (CL:0000312)
• Fibroblast / cancer-associated fibroblast (CL:0000057; CAF is a functional state) (dongre2020establishmentofa pages 1-7)
• CD8-positive, alpha-beta T cell (CL:0000625) (prognostic immune infiltrate context) (zhang2023anintegratedmodel pages 1-2)

5. Environmental Information

Infectious agents

• High-risk HPV is a key infectious driver of the HPV-associated VSCC pathway. (dongre2024tp53mutationand pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

Lifestyle factors

• Smoking is cited as a risk factor in clinical updates and reviews. (olawaiye2021cancerofthe pages 1-2)

Non-infectious inflammatory conditions

• Chronic inflammatory vulvar dermatoses, especially lichen sclerosus, are strongly linked to HPV-independent carcinogenesis and functional morbidity. (luca2023lichensclerosusthe pages 1-2)

6. Mechanism / Pathophysiology

Key mechanisms and pathways

• PI3K/AKT/mTOR signaling: implicated particularly in HPV-associated tumors via PIK3CA activating mutations, and in a subset of HPV-independent cases. (salama2022molecularlandscapeof pages 1-3, fujii2024genomicprofilesof pages 1-2)
• RAS/MAPK signaling: HRAS mutations occur in a subset of VSCC. (fujii2024genomicprofilesof pages 1-2)
• TP53 tumor suppressor pathway: frequently altered in HPV-independent VSCC and linked to worse prognosis. (dongre2024tp53mutationand pages 1-2, fujii2024genomicprofilesof pages 1-2)
• NOTCH pathway: frequently altered in HPV-independent disease in sequencing cohorts, consistent with altered squamous differentiation programs. (salama2022molecularlandscapeof pages 1-3)

Tumor microenvironment and stromal dependence

Experimental evidence supports a strong role for tumor–stroma interaction: a LS-associated VSCC cell line (VCC1) showed fibroblast-dependent invasion and tumor formation in 3D organotypic models and xenografts. (dongre2020establishmentofa pages 1-7)

7. Anatomical Structures Affected

Organ / tissue level

• Primary site: vulva (labia majora/minora, clitoris, perineum, mons). (corte2024currentpreoperativemanagement pages 1-2)
• Regional spread: lymphatic drainage primarily to inguinofemoral nodes, secondarily to pelvic nodes. (olawaiye2021cancerofthe pages 1-2)

Suggested UBERON terms (examples)

• Vulva (UBERON:0000997)
• Labium majus (UBERON:0003185)
• Labium minus (UBERON:0003186)
• Clitoris (UBERON:0002256)
• Inguinal lymph node (UBERON:0001542)

8. Temporal Development

• Onset: typically adult/geriatric; HPV-associated pathway tends to present earlier than HPV-independent. (dongre2024tp53mutationand pages 1-2)
• Progression and precursors: HSIL/uVIN and dVIN are recognized precursors; dVIN has higher malignant potential and faster progression than HSIL in comparative data summarized by reviews. (scurtu2024squamouscellcarcinoma pages 4-5)

9. Inheritance and Population

Epidemiology (selected recent statistics)

• A 2024 imaging review cites 47,000 global vulvar cancer cases in 2022. (ha2024imaginginvulval pages 1-2)
• A single-center “patterns of care” study cites GLOBOCAN 2020 estimates (45,240 cases; 17,427 deaths). (singhal2024patternsofcare pages 1-2)

Genetic inheritance is not applicable in a Mendelian sense for most vulvar carcinoma; this is primarily a sporadic, multifactorial cancer with somatic driver alterations.

10. Diagnostics

Diagnostic approach

• Biopsy of any suspicious vulvar lesion is emphasized as essential for diagnosis; vulvoscopy is a key clinical tool. (corte2024currentpreoperativemanagement pages 1-2, olawaiye2021cancerofthe pages 1-2)

Biomarkers used in practice

• p16 immunohistochemistry is used as a surrogate for HPV association; diffuse “block” staining supports HPV-associated neoplasia. (dongre2024tp53mutationand pages 1-2, hohn20212020whoclassification pages 4-6)
• p53 immunohistochemistry helps identify HPV-independent/TP53-altered tumors and precursor lesions such as dVIN. (horn2024molecularsubtypesof pages 16-18)

Imaging (preoperative and staging)

Imaging recommendations vary by stage and clinical question; a 2024 preoperative management review identifies MRI and PET as gold-standard imaging for local extension and nodal evaluation, with expert-performed ultrasound increasingly used for groin node assessment. (corte2024currentpreoperativemanagement pages 1-2)

The FIGO 2021 staging revision explicitly allows staging to incorporate cross-sectional imaging findings. (olawaiye2021figostagingfor pages 1-2)

The following table (from the 2024 imaging review) summarizes FIGO 2021 staging.

(ha2024imaginginvulval media e360c86b)

Differential diagnosis (selected)

Vulvar lesions that can mimic malignant or premalignant disease include inflammatory dermatoses (e.g., lichen sclerosus) and premalignant vulvar intraepithelial lesions; biopsy is required when neoplasia is suspected. (luca2023lichensclerosusthe pages 1-2)

11. Outcome / Prognosis

Prognostic factors

• Nodal status is critical: one systematic review states 5-year OS is >80% node-negative, <40% with inguinal node involvement, and 10–15% with pelvic nodes. (ferrari2024adjuvantradiotherapyfor pages 1-2)
• Molecular subtype impacts prognosis: TP53 mutation status is an independent adverse prognostic factor for progression-free survival, and transcriptionally active hrHPV is associated with improved outcomes in a 2024 cohort. (dongre2024tp53mutationand pages 1-2)

Recent quantitative survival / outcome statistics

• SEER-derived survival cited in a guideline comparison: 5-year survival 85.6% localized, 47.5% regional, 23.3% distant (stage IVB). (restaino2025managementofpatients pages 2-4)
• A single-center cohort (n=82) reported: disease-specific recurrence 32.9%, mortality 30.5%, median DFS 17 months, median OS 27 months. (singhal2024patternsofcare pages 1-2)
• In metastatic vulvar cancer (SEER 2000–2019), chemoradiotherapy improved OS vs radiotherapy alone (matched cohort HR 0.7367, 95% CI 0.5906–0.9190). (meng2024overallsurvivalassociated pages 1-2)

12. Treatment

Current standard-of-care (real-world implementations)

Surgery - Early-stage disease: local excision / radical local excision with attention to margins, plus groin staging when indicated. (kolk2024updateonthe pages 1-2, ferrari2024adjuvantradiotherapyfor pages 1-2)

Sentinel lymph node biopsy (SLNB) - SLNB is an established, less morbid alternative to inguinofemoral lymphadenectomy in selected early-stage VSCC; it reduces complications such as lymphedema while maintaining oncologic safety. (kolk2024updateonthe pages 1-2)

Radiotherapy / chemoradiotherapy - Adjuvant radiotherapy for nodal disease has limited RCT evidence but suggests reduction in cancer-related deaths and groin recurrences; one RCT reported 6-year cancer-related deaths 29% vs 51% (HR 0.49) and groin recurrences 5.3% vs 24.1% favoring radiotherapy. (ferrari2024adjuvantradiotherapyfor pages 1-2) - For locally advanced unresectable disease, multiple guideline sets recommend definitive chemoradiation. (restaino2025managementofpatients pages 14-16)

Systemic therapy and immunotherapy (emerging) - Modern guidance notes emerging immunotherapy options for advanced disease, but evidence remains limited and often extrapolated from other SCC sites; clinical trials are ongoing. (restaino2025managementofpatients pages 2-4)

Active / planned clinical trials (selected)

• NCT07101848 (BRAVA VULVAR): Phase II randomized maintenance cemiplimab vs best supportive care after 1st-line platinum chemotherapy in advanced/recurrent vulvar cancer; primary endpoint PFS at week 24; not yet recruiting; estimated start 2025-11-01. URL: https://clinicaltrials.gov/study/NCT07101848 (NCT07101848 chunk 1)
• NCT05903833: Phase II single-arm pembrolizumab + lenvatinib in recurrent/metastatic/locally advanced VSCC not amenable to curative surgery/radiotherapy; primary endpoint ORR within 24 weeks; recruiting; start 2025-06-24. URL: https://clinicaltrials.gov/study/NCT05903833 (NCT05903833 chunk 1)
• NCT07290894 (MITO VULVA-01): Phase II single-arm multi-cohort pembrolizumab + lenvatinib across unresectable locally advanced, chemo-naïve metastatic, and post-chemo recurrent/metastatic cohorts; primary endpoint ORR by RECIST 1.1; recruiting; start 2026-03-12. URL: https://clinicaltrials.gov/study/NCT07290894 (NCT07290894 chunk 1)

MAXO (Medical Action Ontology) suggestions (examples)

(Provide as ontology suggestions; confirm IDs in MAXO.) - Surgical excision / wide local excision; radical vulvectomy - Sentinel lymph node biopsy - External beam radiotherapy - Concurrent chemoradiotherapy - Immune checkpoint inhibitor therapy (anti–PD-1)

13. Prevention

Primary prevention

• HPV vaccination is the primary preventive tool for HPV-associated vulvar precancers/cancers, with very high efficacy in HPV-naïve individuals and broad global adoption but incomplete coverage. (adekanmbi2024humanpapillomavirusvaccination pages 1-2, cai2024humanpapillomavirusrelatedcancer pages 1-2)

Secondary/tertiary prevention

• There is no population screening program for vulvar cancer; prevention relies on early identification and management of predisposing conditions/precursors and biopsy of suspicious lesions. (olawaiye2021cancerofthe pages 1-2)
• For LS, long-term potent topical corticosteroids are standard and cohorts/reviews emphasize surveillance; LS has strong symptom burden and elevated malignancy risk. (luca2023lichensclerosusthe pages 1-2, popa2024vulvarlichensclerosus pages 21-22)

14. Other Species / Natural Disease

No naturally occurring non-human species disease data were identified in the retrieved sources for vulvar carcinoma specifically.

15. Model Organisms / Experimental Models

Cell lines, organotypic models, xenografts

• A LS-associated VSCC cell line (VCC1) was established and shown to have fibroblast-dependent tumorigenic and invasive behavior in 3D collagen co-culture/organotypic assays and xenografts, highlighting cancer-associated fibroblast contributions. URL: https://doi.org/10.1016/j.yexcr.2019.111684 (Published Jan 2020). (dongre2020establishmentofa pages 1-7)
• The A431 cell line is used as a vulvar SCC model in mechanistic studies; one report shows miR-4712-5p promotes proliferation/invasion by targeting PTEN and activating AKT/cyclin D1 signaling. URL: https://doi.org/10.3892/or.2019.7320 (Published Sep 2019). (yang2019microrna47125ppromotesproliferation pages 1-2)

Suggested uses

• Tumor–stroma interaction experiments (CAF co-culture)
• Pathway perturbation (PI3K/AKT, RAS/MAPK)
• Immunotherapy biomarker exploration (PD-L1, TILs) and radiosensitivity hypotheses by subtype

Summary artifact (identifiers, subtypes, genomics)

Table: This table compiles core identifiers, current subtype terminology, biomarker definitions, and recurrent genomic alterations for vulvar carcinoma/VSCC. It is useful as a compact reference for disease ontology, clinicopathologic stratification, and precision-oncology annotation.

References

1. (corte2024currentpreoperativemanagement pages 1-2): Luigi Della Corte, Valeria Cafasso, Maria Chiara Guarino, Giuseppe Gullo, Gaspare Cucinella, Alessandra Lopez, Simona Zaami, Gaetano Riemma, Pierluigi Giampaolino, and Giuseppe Bifulco. Current preoperative management of vulvar squamous cell carcinoma: an overview. Cancers, 16:1846, May 2024. URL: https://doi.org/10.3390/cancers16101846, doi:10.3390/cancers16101846. This article has 12 citations.

2. (steinkasserer2023characterizationofpatients pages 1-2): L. Steinkasserer, J. Hachenberg, P. Hillemanns, and M. Jentschke. Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis. Archives of Gynecology and Obstetrics, 307:1921-1928, Nov 2023. URL: https://doi.org/10.1007/s00404-022-06848-y, doi:10.1007/s00404-022-06848-y. This article has 20 citations and is from a peer-reviewed journal.

3. (adekanmbi2024humanpapillomavirusvaccination pages 1-2): Victor Adekanmbi, Itunu Sokale, Fangjian Guo, Jessica Ngo, Thao N. Hoang, Christine D. Hsu, Abiodun Oluyomi, and Abbey B. Berenson. Human papillomavirus vaccination and human papillomavirus–related cancer rates. JAMA Network Open, 7:e2431807, Sep 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.31807, doi:10.1001/jamanetworkopen.2024.31807. This article has 13 citations and is from a peer-reviewed journal.

4. (ha2024imaginginvulval pages 1-2): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

5. (olawaiye2021figostagingfor pages 1-2): A. Olawaiye, J. Cotler, M. Cuello, N. Bhatla, A. Okamoto, S. Wilailak, C. Purandare, G. Lindeque, J. Berek, S. Kehoe, S. Kehoe, A. Olawaiye, M. Cuello, N. Bhatla, A. Okamoto, S. Wilailak, G. Lindeque, J. Berek, C. Purandare, and J. Cain. Figo staging for carcinoma of the vulva: 2021 revision. International Journal of Gynaecology and Obstetrics, 155:43-47, Sep 2021. URL: https://doi.org/10.1002/ijgo.13880, doi:10.1002/ijgo.13880. This article has 129 citations.

6. (dongre2024tp53mutationand pages 1-2): Harsh Nitin Dongre, Rammah Elnour, Stian Tornaas, Siren Fromreide, Liv Cecilie Vestrheim Thomsen, Ingrid Benedicte Moss Kolseth, Elisabeth Sivy Nginamau, Anne Christine Johannessen, Olav Karsten Vintermyr, Daniela Elena Costea, and Line Bjørge. Tp53 mutation and human papilloma virus status as independent prognostic factors in a norwegian cohort of vulva squamous cell carcinoma. Acta Obstetricia et Gynecologica Scandinavica, 103:165-175, Oct 2024. URL: https://doi.org/10.1111/aogs.14689, doi:10.1111/aogs.14689. This article has 14 citations and is from a domain leading peer-reviewed journal.

7. (meng2024overallsurvivalassociated pages 1-2): Xiaolin Meng, Shuaiqingying Guo, Xue Feng, Jihui Ai, and Jie Yang. Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: a retrospective cohort study based on the seer database. Cancer Pathogenesis and Therapy, 2:195-204, Jul 2024. URL: https://doi.org/10.1016/j.cpt.2023.08.003, doi:10.1016/j.cpt.2023.08.003. This article has 6 citations.

8. (dongre2020establishmentofa pages 1-7): Harsh Dongre, Neha Rana, Siren Fromreide, Saroj Rajthala, Ingeborg Bøe Engelsen, Justine Paradis, J. Silvio Gutkind, Olav Karsten Vintermyr, Anne Christine Johannessen, Line Bjørge, and Daniela Elena Costea. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research, 386:111684, Jan 2020. URL: https://doi.org/10.1016/j.yexcr.2019.111684, doi:10.1016/j.yexcr.2019.111684. This article has 12 citations and is from a peer-reviewed journal.

9. (horn2024molecularsubtypesof pages 12-14): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.

10. (hohn20212020whoclassification pages 4-6): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 487 citations and is from a peer-reviewed journal.

11. (horn2024molecularsubtypesof pages 16-18): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.

12. (scurtu2024squamouscellcarcinoma pages 5-7): Lucian G. Scurtu, Francesca Scurtu, Sebastian Catalin Dumitrescu, and Olga Simionescu. Squamous cell carcinoma in situ—the importance of early diagnosis in bowen disease, vulvar intraepithelial neoplasia, penile intraepithelial neoplasia, and erythroplasia of queyrat. Diagnostics, 14:1799, Aug 2024. URL: https://doi.org/10.3390/diagnostics14161799, doi:10.3390/diagnostics14161799. This article has 11 citations.

13. (luca2023lichensclerosusthe pages 1-2): David A. De Luca, Cristian Papara, Artem Vorobyev, Hernán Staiger, Katja Bieber, Diamant Thaçi, and Ralf J. Ludwig. Lichen sclerosus: the 2023 update. Frontiers in Medicine, Feb 2023. URL: https://doi.org/10.3389/fmed.2023.1106318, doi:10.3389/fmed.2023.1106318. This article has 234 citations.

14. (scurtu2024squamouscellcarcinoma pages 4-5): Lucian G. Scurtu, Francesca Scurtu, Sebastian Catalin Dumitrescu, and Olga Simionescu. Squamous cell carcinoma in situ—the importance of early diagnosis in bowen disease, vulvar intraepithelial neoplasia, penile intraepithelial neoplasia, and erythroplasia of queyrat. Diagnostics, 14:1799, Aug 2024. URL: https://doi.org/10.3390/diagnostics14161799, doi:10.3390/diagnostics14161799. This article has 11 citations.

15. (cai2024humanpapillomavirusrelatedcancer pages 1-2): Xia Cai and Ling Xu. Human papillomavirus-related cancer vaccine strategies. Vaccines, 12 11:1291, Nov 2024. URL: https://doi.org/10.3390/vaccines12111291, doi:10.3390/vaccines12111291. This article has 14 citations.

16. (popa2024vulvarlichensclerosus pages 21-22): Adelina Popa, Mihai Dumitrascu, Aida Petca, Razvan-Cosmin Petca, and Florica Sandru. Vulvar lichen sclerosus: navigating sex hormone dynamics and pioneering personalized treatment paradigm. Journal of Personalized Medicine, 14:76, Jan 2024. URL: https://doi.org/10.3390/jpm14010076, doi:10.3390/jpm14010076. This article has 21 citations.

17. (olawaiye2021cancerofthe pages 1-2): Alexander B. Olawaiye, Mauricio A. Cuello, and Linda J. Rogers. Cancer of the vulva: 2021 update. International Journal of Gynaecology and Obstetrics, 155:7-18, Oct 2021. URL: https://doi.org/10.1002/ijgo.13881, doi:10.1002/ijgo.13881. This article has 247 citations.

18. (cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4): Marta Cebolla-Verdugo, Victor Alfredo Cassini-Gómez de Cádiz, Juan Pablo Velasco-Amador, María Zulaika-Lloret, Francisco Manuel Almazán-Fernández, and Ricardo Ruiz-Villaverde. Multidisciplinary vulvar cancer management: the dermatologist’s perspective. Life, 15:19, Dec 2024. URL: https://doi.org/10.3390/life15010019, doi:10.3390/life15010019. This article has 1 citations.

19. (kolk2024updateonthe pages 1-2): Willemijn L. van der Kolk, Joost Bart, Ate J.G. van der Zee, and Maaike H.M. Oonk. Update on the sentinel node procedure in vulvar cancer. Journal of the National Comprehensive Cancer Network : JNCCN, Mar 2024. URL: https://doi.org/10.6004/jnccn.2024.7002, doi:10.6004/jnccn.2024.7002. This article has 2 citations.

20. (fujii2024genomicprofilesof pages 1-2): Erisa Fujii, Mayumi Kobayashi Kato, Maiko Yamaguchi, Daiki Higuchi, Takafumi Koyama, Masaaki Komatsu, Ryuji Hamamoto, Mitsuya Ishikawa, Tomoyasu Kato, Takashi Kohno, Kouya Shiraishi, and Hiroshi Yoshida. Genomic profiles of japanese patients with vulvar squamous cell carcinoma. Scientific Reports, Jun 2024. URL: https://doi.org/10.1038/s41598-024-63913-z, doi:10.1038/s41598-024-63913-z. This article has 1 citations and is from a peer-reviewed journal.

21. (salama2022molecularlandscapeof pages 1-3): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

22. (zhang2023anintegratedmodel pages 1-2): Tao Zhang, Yingfan Zhu, Jie Luo, Juanqing Li, Shuang Niu, Hao Chen, and Feng Zhou. An integrated model for prognosis in vulvar squamous cell carcinoma. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-11039-2, doi:10.1186/s12885-023-11039-2. This article has 9 citations and is from a peer-reviewed journal.

23. (singhal2024patternsofcare pages 1-2): Seema Singhal, Daya Nand Sharma, Sandeep Mathur, Swati Tomar, Jyoti Meena, Anju Singh, and Neerja Bhatla. Patterns of care for vulvar cancer and insights from revised figo staging: a retrospective study. World Journal of Surgical Oncology, Dec 2024. URL: https://doi.org/10.1186/s12957-024-03612-1, doi:10.1186/s12957-024-03612-1. This article has 3 citations and is from a peer-reviewed journal.

24. (ha2024imaginginvulval media e360c86b): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

25. (ferrari2024adjuvantradiotherapyfor pages 1-2): Federico Ferrari, Lamiese Ismail, Ahmad Sabbagh, Kieran Hardern, Robert Owens, Elisa Gozzini, and Hooman Soleymani Majd. Adjuvant radiotherapy for groin node metastases following surgery for vulvar cancer: a systematic review. Oncology Reviews, May 2024. URL: https://doi.org/10.3389/or.2024.1389035, doi:10.3389/or.2024.1389035. This article has 3 citations.

26. (restaino2025managementofpatients pages 2-4): Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Rosa Pasqualina De Vincenzo, Giorgia Garganese, Francesco Sopracordevole, Violante Di Donato, Andrea Ciavattini, Paolo Scollo, Giovanni Scambia, and Giuseppe Vizzielli. Management of patients with vulvar cancers: a systematic comparison of international guidelines (nccn–asco–esgo–bgcs–igcs–figo–french guidelines–rcog). Cancers, 17:186, Jan 2025. URL: https://doi.org/10.3390/cancers17020186, doi:10.3390/cancers17020186. This article has 23 citations.

27. (restaino2025managementofpatients pages 14-16): Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Rosa Pasqualina De Vincenzo, Giorgia Garganese, Francesco Sopracordevole, Violante Di Donato, Andrea Ciavattini, Paolo Scollo, Giovanni Scambia, and Giuseppe Vizzielli. Management of patients with vulvar cancers: a systematic comparison of international guidelines (nccn–asco–esgo–bgcs–igcs–figo–french guidelines–rcog). Cancers, 17:186, Jan 2025. URL: https://doi.org/10.3390/cancers17020186, doi:10.3390/cancers17020186. This article has 23 citations.

28. (NCT07101848 chunk 1): A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER. Hospital Israelita Albert Einstein. 2025. ClinicalTrials.gov Identifier: NCT07101848

29. (NCT05903833 chunk 1): Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy. AGO Research GmbH. 2025. ClinicalTrials.gov Identifier: NCT05903833

30. (NCT07290894 chunk 1): Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01. National Cancer Institute, Naples. 2026. ClinicalTrials.gov Identifier: NCT07290894

31. (yang2019microrna47125ppromotesproliferation pages 1-2): Shaojie Yang, Yanyan Zhao, Lufang Wang, Chang Liu, Ye Lu, Zhidong Fang, Hongshuang Shi, Wenyi Zhang, and Xin Wu. Microrna-4712-5p promotes proliferation of the vulvar squamous cell carcinoma cell line a431 by targeting pten through the akt/cyclin d1 signaling pathways. Oncology Reports, 42:1689-1698, Sep 2019. URL: https://doi.org/10.3892/or.2019.7320, doi:10.3892/or.2019.7320. This article has 13 citations and is from a peer-reviewed journal.

32. (faruqiUnknownyear2021figostaging pages 1-5): BRRGA Faruqi, M Eden, and SSANW Glenn. 2021 figo staging system for vulvar cancer: summary and comparison with 2009 figo staging system. Unknown journal, Unknown year.

33. (horn2024molecularsubtypesof pages 1-5): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.

34. (hohn20212020whoclassification pages 1-2): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 487 citations and is from a peer-reviewed journal.

35. (salama2022molecularlandscapeof pages 4-6): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

36. (salama2022molecularlandscapeof pages 8-10): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

37. (farkas2025pathologicalvariantsin pages 8-9): Sanja A. Farkas, Alvida Qvick, Gisela Helenius, and Gabriella Lillsunde-Larsson. Pathological variants in hpv-independent vulvar tumours. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-024-84688-3, doi:10.1038/s41598-024-84688-3. This article has 3 citations and is from a peer-reviewed journal.

38. (farkas2025pathologicalvariantsin pages 7-8): Sanja A. Farkas, Alvida Qvick, Gisela Helenius, and Gabriella Lillsunde-Larsson. Pathological variants in hpv-independent vulvar tumours. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-024-84688-3, doi:10.1038/s41598-024-84688-3. This article has 3 citations and is from a peer-reviewed journal.